Diffuse Large B Cell Lymphoma Survival

For years, researchers have been looking for the right biomarkers to make the most accurate predictions of diffuse large B cell lymphoma survival rates among patients.

R-IPI as a Predictor of Diffuse Large B Cell Lymphoma Survival

One method for determining diffuse large B cell lymphoma survival in patientsis by using what is known as the Revised International Prognostic Index. The relative accuracy of this index has been supported by several subsequent studies. The R-IPI can be more closely examined at this page.

Moleculor Expression as a Predictor for Diffuse Large B Cell Lymphoma Survival

Seeking prognostic indicators of value has not been easy for researchers, but according to the resuls of a paper published in 2009, at least one marker, found by way of pathologic techniques known as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

What they determined was that no single, individual protein marker found on cell surfaces (identified with CD placed before the number, such as "CD20") could be associated with diffuse large B cell lymphoma survival, and nor could two common chromosomal translocations, BCL-2 or c-MYC. However, the presence of the chromosomal translocation BCL-6 in fact does correlate with a poorer prognosis and poorer 5 year diffuse large B cell lymphoma survival rates than in patients with no BLC-6 translocation.

Sources

Sehn LH et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857-61.

Copie-Bergman C et al. Index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. . J Clin Oncol 2009 Sep 28.

More Articles

More Articles

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

Diagnosing lymphoma is one of the more difficult diagnoses to make in cancer medicine, and contrary to perception, diagnosing lymphoma is not made...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Follicular lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

Lymphoma is not difficult to diagnose once a patient and doctor begin to look for signs of cancer. However, Lymphoma–especially...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...